| Primary | Average Knee Pain While Walking | All subjects were asked to complete daily diaries to record their average pain intensity while walking during the past 24 hours on each day of a 7-day period using an 11-point numerical rating scale where 0 represents "No Pain" and 10 represents "Pain as bad as you can imagine." For each subject, the mean score for each diary period was calculated and a mean of all four diary periods was calculated (weeks 1-4). The mean group scores for weeks 1-4 are reported. | | Posted | | Mean | Standard Deviation | Scores on a scale | | Postoperative Day 0 to 28 (first 4 weeks following Total Knee Arthroplasty (TKA) | | | | ID | Title | Description |
|---|
| OG000 | Treatment Group | Subjects in the Treatment Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects had at least one Lead placed in their affected leg prior to TKA and used the SPRINT Beta System to receive electrical stimulation therapy in addition to the standard of care. | | OG001 | Control Group | Subjects in the Control Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects did not undergo Lead placement, and they received the standard of care following TKA. |
| | | Title | Denominators | Categories |
|---|
| | | Title | Measurements |
|---|
| - OG0003.70± 1.97
- OG0014.14± 1.49
|
|
| |
| Primary | Number of Subjects That Experienced at Least One Study-Related Adverse Event | At each study visit following the baseline assessment at Visit 1, subjects were questioned if any changes in their medical status or condition has occurred since their previous visit. If the subject experienced a change that was an adverse event, an Adverse Event Form was completed by the site. The number of Treatment Group subjects that experienced at least one study-related adverse event is reported here. | All enrolled Treatment Group subjects | Posted | | Count of Participants | | Participants | | 30 months (from when the first Treatment Group subject enrolled to when the last Treatment Group subject completed the study) | | | | ID | Title | Description |
|---|
| OG000 | Treatment Group | Subjects in the Treatment Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects had at least one Lead placed in their affected leg prior to TKA and used the SPRINT Beta System to receive electrical stimulation therapy in addition to the standard of care. |
| |
| Secondary | Average Knee Pain Over the Last 24 Hours | All subjects were asked to complete daily diaries to track their average pain intensity during the past 24 hours over a 7-day period on an 11-point numerical rating scale where 0 represents "No Pain" and 10 represents "Pain as bad as you can imagine." The average score for each diary period was calculated across subjects, and the mean score for weeks 1-4 is reported. | | Posted | | Mean | Standard Deviation | score on a scale | | Postoperative Day 0 to 28 (first 4 weeks following Total Knee Arthroplasty (TKA)) | | | | ID | Title | Description |
|---|
| OG000 | Treatment Group | Subjects in the Treatment Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects had at least one Lead placed in their affected leg prior to TKA and used the SPRINT Beta System to receive electrical stimulation therapy in addition to the standard of care. | | OG001 | Control Group | Subjects in the Control Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects did not undergo Lead placement, and they received the standard of care following TKA. |
| |
| Secondary | Average Knee Pain at Rest | All subjects were asked to complete daily diaries to track their average pain intensity at rest during the past 24 hours over a 7-day period on an 11-point numerical rating scale where 0 represents "No Pain" and 10 represents "Pain as bad as you can imagine." The average score for each diary period was calculated across subjects, and the mean score for weeks 1-4 is reported. | | Posted | | Mean | Standard Deviation | score on a scale | | Postoperative Day 0 to 28 (first 4 weeks following Total Knee Arthroplasty (TKA)) | | | | ID | Title | Description |
|---|
| OG000 | Treatment Group | Subjects in the Treatment Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects had at least one Lead placed in their affected leg prior to TKA and used the SPRINT Beta System to receive electrical stimulation therapy in addition to the standard of care. | | OG001 | Control Group | Subjects in the Control Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects did not undergo Lead placement, and they received the standard of care following TKA. |
| |
| Secondary | Pain Right Now as Measured by the Brief Pain Inventory | Subjects were asked to rate their pain right now on an 11-point numerical scale where 0 represents "No Pain" and 10 represents "Pain as bad as you can imagine." The median score for each time point is reported. Baseline is considered Visit 2a (Lead Placement) for Treatment Group subjects and Visit 2b for Control Group subjects. For Treatment Group subjects for Visits 3, 4, 6, and 8, pain right now was assessed while peripheral nerve stimulation was on for at least one Lead. For Visit 4, the score reported during the last in-hospital day was used. | Per Protocol Set - Data were not available for one Treatment Group subject at Visit 3 and for one Control Group subject at Visit 6. | Posted | | Median | Full Range | Scores on a scale | | Baseline (Visit 2a/2b), Visit 3 (Day of Total Knee Arthroplasty (TKA)), Visit 4 (in-hospital), Visit 6 (2-weeks post TKA), and Visit 8 (4-weeks post TKA) | | | | ID | Title | Description |
|---|
| OG000 | Treatment Group | Subjects in the Treatment Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects had at least one Lead placed in their affected leg prior to TKA and used the SPRINT Beta System to receive electrical stimulation therapy in addition to the standard of care. | | OG001 | Control Group | Subjects in the Control Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects did not undergo Lead placement, and they received the standard of care following TKA. |
|
| Secondary | Amount of Analgesic Usage | Subjects recorded the amount/type of analgesics used in daily diaries. Narcotic usage was converted into morphine milligram equivalents (MME). Diaries were collected at various visits and were translated into post-operative days. The average MME was calculated for each subject for the first 28 days (4 weeks) following surgery, and the median of these averages across subjects was determined. If subjects had ceased opioid use (per the Recovery Milestones log), then missing scores following the date of opioid cessation were replaced with 0 MME. If diary entries were missing but the subject had not yet reported opioid cessation, then the missing value was replaced with the mean usage of the available days for the corresponding week. Subjects missing data from one or more entire diaries (i.e., weeks) and had not yet reported opioid cessation by the date of any missing diary were not included in this analysis. | Per Protocol Set - Data were not available for one Control Group subject at Visits 6-8. | Posted | | Median | Full Range | MME | | Visits 5-8 (weeks 1-4 post-Total Knee Arthroplasty (TKA)) | | | | ID | Title | Description |
|---|
| OG000 | Treatment Group | Subjects in the Treatment Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects had at least one Lead placed in their affected leg prior to TKA and used the SPRINT Beta System to receive electrical stimulation therapy in addition to the standard of care. | | OG001 | Control Group |
|
| Secondary | Number of Subjects That Experienced at Least One Opioid-Related Side Effect | Throughout the study, subjects were asked if they experienced any side effects related to opioid pain medications. The occurrences of these side effects were recorded and were not considered Adverse Events. The number of subjects that experienced at least one opioid-related side effect at each visit is reported. Baseline is considered Visit 2a (Lead Placement) for Treatment Group subjects and Visit 2b for Control Group subjects. | Per Protocol Set - Data were not available for one Treatment Group subject at Visit 6 and Visit 11. Data were not available for the following Control Group subjects: one at Visits 5, 6, 7, and 9, and three at Visits 10 and 11. | Posted | | Count of Participants | | Participants | | Baseline (Visit 2a/2b), Visits 4-11 (in-hospital days through 12-months post-Total Knee Arthroplasty (TKA)) | | | | ID | Title | Description |
|---|
| OG000 | Treatment Group | Subjects in the Treatment Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects had at least one Lead placed in their affected leg prior to TKA and used the SPRINT Beta System to receive electrical stimulation therapy in addition to the standard of care. | | OG001 | Control Group | Subjects in the Control Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects did not undergo Lead placement, and they received the standard of care following TKA. |
|
| Secondary | Timed Up and Go (TUG) Test | Subjects began this test from a seated position in a standard chair and were timed while they stood up, walked to a marked point 10 feet away (at a normal, safe pace), returned to the chair, and sat down. Timed Up and Go (TUG) test times are expected to be greater immediately after surgery as compared to baseline. | Per Protocol Set - Data were not available for the following Control Group subjects: one at Visit 1 (subject was unable to complete test), three at Visit 4 (two subjects were unable to complete test), and one at Visit 6. | Posted | | Median | Inter-Quartile Range | seconds | | Visit 1 (Baseline), Visit 4 (In-Hospital), Visit 6 (2-weeks Post-Total Knee Arthroplasty (TKA)), Visit 8 (4-weeks Post-TKA) | | | | ID | Title | Description |
|---|
| OG000 | Treatment Group | Subjects in the Treatment Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects had at least one Lead placed in their affected leg prior to TKA and used the SPRINT Beta System to receive electrical stimulation therapy in addition to the standard of care. | | OG001 | Control Group | Subjects in the Control Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects did not undergo Lead placement, and they received the standard of care following TKA. |
|
| Secondary | Six Minute Walk Test (6MWT) | The total distance that a subject could walk in 6 minutes was recorded, and subjects unable to walk at all were given a score of 0 meters. The median distance was then determined across subjects. 6 Minute Walk Test distances are expected to be reduced immediately after surgery as compared to baseline. | Per Protocol Set - Data were not available for one Control Group subject at Visit 6. | Posted | | Median | Full Range | meters | | Visit 1 (Baseline), Visit 6 (2-weeks Post-Total Knee Arthroplasty (TKA)), Visit 8 (4-weeks post-TKA) | | | | ID | Title | Description |
|---|
| OG000 | Treatment Group | Subjects in the Treatment Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects had at least one Lead placed in their affected leg prior to TKA and used the SPRINT Beta System to receive electrical stimulation therapy in addition to the standard of care. | | OG001 | Control Group | Subjects in the Control Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects did not undergo Lead placement, and they received the standard of care following TKA. |
| |
| Secondary | Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) | The Western Ontario McMaster University Osteoarthritis Index (WOMAC) questionnaire consists of 24 items that evaluate pain, stiffness, and physical functional disability. Each item is scored on an 11-point numerical rating scale from 0 to 10, where higher scores indicate greater pain, stiffness, and disability. For each subject, the scores from each of the 24 items were summed to calculate the subject's total score, with a minimum score of 0 and a maximum score of 240. The mean total score was then calculated across subjects for each time point. | Per Protocol Set - Data were not available for one Treatment Group subject at Visit 11. Data were not available for the following Control Group subjects: three at Visit 3, one at Visit 6, three at Visit 10, and two at Visit 11. | Posted | | Mean | Standard Deviation | score on a scale | | Visit 1 (Baseline), Visit 3 (Day of Total Knee Arthroplasty (TKA)), Visit 6 (2-weeks post-TKA), Visit 8 (4-weeks post-TKA), Visit 10 (3-months post-TKA), and Visit 11 (12-months post-TKA) | | | | ID | Title | Description |
|---|
| OG000 | Treatment Group | Subjects in the Treatment Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects had at least one Lead placed in their affected leg prior to TKA and used the SPRINT Beta System to receive electrical stimulation therapy in addition to the standard of care. | | OG001 | Control Group |
|
| Secondary | Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey | The Patient Global Impression of Change (PGIC) asks subjects to rate their improvement with treatment on a 7-point scale ranging from "very much worse" to "very much improved" as compared to before their knee replacement surgery. The subjects combine all the components of their experience into one overall score. Ratings of Much- or Very Much Improved are considered "Meaningful Improvements"; similarly, ratings of Much- or Very Much Worse are categorized as "Meaningfully Worse." Ratings of Minimally Improved, No Change, or Minimally Worse are considered "Minimal or No Change." | Per Protocol Set: Data were not available for one Treatment Group subject at Visit 11. Data were not available for the following Control Group subjects: one at Visit 4, one at Visit 6, one at Visit 9, three at Visit 10, and two at Visit 11. | Posted | | Count of Participants | | Participants | | Visits 3-11 (Day of Total Knee Arthroplasty (TKA) through 12-months post-TKA) | | | | ID | Title | Description |
|---|
| OG000 | Treatment Group | Subjects in the Treatment Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects had at least one Lead placed in their affected leg prior to TKA and used the SPRINT Beta System to receive electrical stimulation therapy in addition to the standard of care. | | OG001 | Control Group |
|
| Secondary | Pain Catastrophizing Scale (PCS) | The Pain Catastrophizing Scale (PCS) questionnaire has 13 questions that assess rumination, magnification, and helplessness. Subjects are asked to think back on painful experiences in the past and reflect on how often they had specific thoughts or feelings. Each of the 13 questions is scored on a 5-point scale where 0 represents "not at all," and 4 represents "all the time." The scores from each question were summed for each subject to provide a total PCS score, with a possible range from 0 to 52 with higher scores indicating a greater tendency to catastrophize pain (i.e. a higher score indicates a worse outcome). The median scores were then calculated across all subjects. | Per Protocol Set - Data were not available for three Control Group subjects at Visit 10. | Posted | | Median | Full Range | score on a scale | | Visit 1 (Baseline), Visit 8 (4 weeks post-Total Knee Arthroplasty (TKA)), Visit 10 (3-months Post-TKA) | | | | ID | Title | Description |
|---|
| OG000 | Treatment Group | Subjects in the Treatment Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects had at least one Lead placed in their affected leg prior to TKA and used the SPRINT Beta System to receive electrical stimulation therapy in addition to the standard of care. | | OG001 | Control Group | Subjects in the Control Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects did not undergo Lead placement, and they received the standard of care following TKA. |
|
| Secondary | Time to Meet Recovery Milestones up to Twelve Months Post-Total Knee Arthroplasty (TKA) | Participants were queried at each visit from the date of their Total Knee Arthroplasty (TKA) until they met specific, post-surgical recovery milestones. Participants were queried up through the time at which they met each milestone or through their completion of the study, whichever came first (up to twelve months post-surgery). For each milestone, the median number of days between the date of TKA and date to achieve the milestone was calculated. | Per Protocol Set- Treatment Group: Data were not available for: 1 subject in "walked without assistive device", 1 in "cleared to drive". 1 subject did not cease opioids during the study. 5 subjects were retired and did not work. Control Group: Data were not collected for: 3 in "walked without assistive device", 2 in "able to climb stairs", 1 in "cleared to drive", 1 in "opioid cessation" (2 more did not cease opioids during the study). 9 subjects were retired and did not work. | Posted | | Median | Full Range | days | | From Day of Surgery through completion of milestone or 12-months from Day of Surgery, whichever came first | | | | ID | Title | Description |
|---|
| OG000 | Treatment Group | Subjects in the Treatment Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects had at least one Lead placed in their affected leg prior to TKA and used the SPRINT Beta System to receive electrical stimulation therapy in addition to the standard of care. | | OG001 |
|
| Secondary | Subject Satisfaction Survey | Subjects completed a sponsor-developed survey with questions pertaining to their feelings about the treatment they received following total knee arthroplasty (TKA) surgery. Treatment Group subjects were asked to report on their experience using the SPRINT Beta Stimulation System as a method for managing post-surgical pain. Depending on the question, subjects were asked to indicate their agreement with the question (strongly disagree, agree, neutral, disagree, strongly disagree), their comfort with the therapy (very uncomfortable, a little bit uncomfortable, fairly comfortable, very comfortable), or when pain relief was felt (immediately, a few minutes later, a few hours later, more than a day later or never). Responses are presented for Treatment Group subjects for key groups of questions related to the therapy whereby answer options are considered affirmative for strongly agree/agree, very easy/easy, very comfortable/comfortable. | | Posted | | Count of Participants | | Participants | | Visit 8 (4-weeks post-total knee arthroplasty (TKA)) | | | | ID | Title | Description |
|---|
| OG000 | Treatment Group | Subjects in the Treatment Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects had at least one Lead placed in their affected leg prior to TKA and used the SPRINT Beta System to receive electrical stimulation therapy in addition to the standard of care. |
| |
| Secondary | Number of Physical Therapy Sessions Attended Following Total Knee Arthroplasty | Following discharge after total knee arthroplasty (TKA) surgery, subjects were asked to report how many physical therapy sessions they attended since the previous study visit. The median number of physical therapy sessions attended is reported for each group at each time point. | Per Protocol Set - Data were not available for the following Control Group subjects: one at Visit 6, two Visit 9, and three at Visit 10. | Posted | | Median | Full Range | Count of visits | | Visit 5 (1-week post-Total Knee Arthroplasty (TKA)), Visit 6 (2-weeks post-TKA), Visit 7 (3-weeks post-TKA), Visit 8 (4-weeks post-TKA), Visit 9 (2-months post-TKA), and Visit 10 (3-months post-TKA) | | | | ID | Title | Description |
|---|
| OG000 | Treatment Group | Subjects in the Treatment Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects had at least one Lead placed in their affected leg prior to TKA and used the SPRINT Beta System to receive electrical stimulation therapy in addition to the standard of care. | | OG001 | Control Group | Subjects in the Control Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects did not undergo Lead placement, and they received the standard of care following TKA. |
|
| Secondary | Subject's Use of Device (Compliance) | The hours of usage were recorded for each Lead (femoral and sciatic) from the SPRINT Beta stimulator throughout the study to assess the level of subject compliance with the peripheral nerve stimulation therapy. Treatment Group subjects were asked to use the device for up to 24 hrs each day. The stimulator provided the cumulative number of hours in use since the device was activated. For each timepoint for Treatment Group participants (subjects who received stimulation therapy), the median cumulative number of hours of use for each lead is presented for each timepoint. | Per Protocol Set - Treatment Group. Data were not available for the femoral or sciatic Leads for one subject at Visit 4 and two subjects at Visit 6. One subject at Visits 4, 6, 8 did not have a sciatic Lead in place. | Posted | | Median | Full Range | hours | | Visit 4 (In-Hospital), Visit 6 (2-weeks post-Total Knee Arthroplasty (TKA)), and Visit 8 (4-weeks Post-TKA) | | | | ID | Title | Description |
|---|
| OG000 | Treatment Group | Subjects in the Treatment Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects had at least one Lead placed in their affected leg prior to TKA and used the SPRINT Beta System to receive electrical stimulation therapy in addition to the standard of care. |
| |
| Secondary | Inpatient Pain Management Experience Survey (Pain Management During Hospital Stay) | Subjects completed a survey comprised of a subset of questions from the Hospital Consumer Assessment of Healthcare Providers and Systems to assess subject satisfaction with pain management during their time in the hospital for total knee arthroplasty surgery. Questions regarding experience with in-hospital pain management are reported below. | Per Protocol Set - Data were not available for three Control Group subjects. | Posted | | Count of Participants | | Participants | | 1-week post-Total Knee Arthroplasty (TKA) | | | | ID | Title | Description |
|---|
| OG000 | Treatment Group | Subjects in the Treatment Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects had at least one Lead placed in their affected leg prior to TKA and used the SPRINT Beta System to receive electrical stimulation therapy in addition to the standard of care. | | OG001 | Control Group | Subjects in the Control Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects did not undergo Lead placement, and they received the standard of care following TKA. |
| |
| Secondary | Inpatient Pain Management Experience Survey (Pain Medicine During Hospital Stay) | Subjects completed a survey comprised of a subset of questions from the Hospital Consumer Assessment of Healthcare Providers and Systems to assess subject satisfaction with pain management during their time in the hospital for total knee arthroplasty surgery. The number of subjects that responded affirmatively to the following question are reported below: "During this hospital stay, did you need medicine for pain?" | Per Protocol - Data were not available for three Control Group subjects | Posted | | Count of Participants | | Participants | | 1-week post-Total Knee Arthroplasty (TKA) | | | | ID | Title | Description |
|---|
| OG000 | Treatment Group | Subjects in the Treatment Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects had at least one Lead placed in their affected leg prior to TKA and used the SPRINT Beta System to receive electrical stimulation therapy in addition to the standard of care. | | OG001 | Control Group | Subjects in the Control Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects did not undergo Lead placement, and they received the standard of care following TKA. |
| |
| Secondary | Inpatient Pain Management Experience Survey (Discharge Facility) | Subjects completed a survey comprised of a subset of questions from the Hospital Consumer Assessment of Healthcare Providers and Systems to assess subject satisfaction with pain management during their time in the hospital for total knee arthroplasty surgery. The question regarding discharge location following hospital stay is reported below. | Per Protocol Set - Data were not available for three Control Group subjects. | Posted | | Count of Participants | | Participants | | 1-week post-Total Knee Arthroplasty (TKA) | | | | ID | Title | Description |
|---|
| OG000 | Treatment Group | Subjects in the Treatment Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects had at least one Lead placed in their affected leg prior to TKA and used the SPRINT Beta System to receive electrical stimulation therapy in addition to the standard of care. | | OG001 | Control Group | Subjects in the Control Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects did not undergo Lead placement, and they received the standard of care following TKA. |
| |
| Secondary | Inpatient Pain Management Experience Survey (Overall Rating of Hospital) | Subjects completed a survey comprised of a subset of questions from the Hospital Consumer Assessment of Healthcare Providers and Systems to assess subject satisfaction with pain management during their time in the hospital for total knee arthroplasty surgery. As part of this survey, subjects were asked to rate their hospital stay on an 11-point numerical rating scale where 0 represents "worst hospital possible" and 10 represents "best hospital possible." The median score for each group is reported. | Per Protocol Set - Data were not available for three Control Group subjects. | Posted | | Median | Full Range | score on a scale | | 1-week post-Total Knee Arthroplasty (TKA)) | | | | ID | Title | Description |
|---|
| OG000 | Treatment Group | Subjects in the Treatment Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects had at least one Lead placed in their affected leg prior to TKA and used the SPRINT Beta System to receive electrical stimulation therapy in addition to the standard of care. | | OG001 | Control Group | Subjects in the Control Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects did not undergo Lead placement, and they received the standard of care following TKA. |
|